Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.97K
+1.97%+3.50%+22.37%+0.32% 195B
+5.87%+6.59%-21.20%+24.59% 151B
+2.17%+2.44%-2.26%-17.53% 140B
+4.83%+2.13%-56.44%-16.55% 67.09B
+2.59%+5.18%+22.53%+0.04% 54.34B
-0.61%+1.52%-25.97%-31.45% 44.64B
-2.02%-3.56%+8.31%+8.68% 36.91B
+0.31%+0.64%+7.78%+42.30% 37.24B
+1.09%+0.96%-13.87%-19.29% 29.82B
Average +1.06%+2.18%-6.53%-0.99% 83.95B
Weighted average by Cap. +1.50%+3.35%-3.58%+0.17%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
7
  1. Stock Market
  2. Stocks
  3. SCIE Stock